Abstract
Thalassemia is an autosomal recessive disorder associated with gene mutations blocking the synthesis of α- or β-chain of globin. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with Thalassemia. However, HSCT has been limited by human leukocyte antigen (HLA) matching degree. Moreover, the relatively probability of graft rejection and regimen-related adverse reactions in many patients receiving HSCT for Thalassemia are associated with the preconditioning regimens. It is important to choose suitable donors and pretreatments for treatment of thalassemia. In this review, the authors aimed to discuss the alternate HSCT approaches for Thalassemia, including unrelated donor HSCT, related donor HSCT, or umbilical cord blood transplantation(UCBT) and the preconditioning regimens. Key words: Thalassemia; Hematopoietic stem cell transplantation; HLA antigens
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
